Form 4: Exelixis EVP Patrick Haley Sells 32,110 Shares
Statement of Changes in Beneficial Ownership
Exelixis EVP of Commercial Patrick J. Haley sold 32,110 shares of common stock at an average price of $49.81.
Summary
- Patrick J. Haley, EVP of Commercial at Exelixis, Inc., executed a sale of 32,110 shares of common stock.
- The transaction occurred on May 20, 2026, at a weighted average price of $49.81 per share.
- Following the sale, the reporting person retains beneficial ownership of 357,638 shares.
- The total holdings include 356,992 shares underlying restricted stock units (RSUs) and performance-based restricted stock units (PSUs).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale appears to be a routine transaction by an executive rather than a signal of fundamental business deterioration.
Positives
- The reporting person maintains a significant remaining equity stake of 357,638 shares in the company.
Negatives
- The transaction represents a divestment of 32,110 shares by a senior executive.
Risks
- Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock performance, though it is often related to personal financial planning or tax obligations.
Future Outlook
The filing does not provide forward-looking financial guidance or operational outlook.
Industry Context
StockSavvy.ai notes that executive stock sales are common in the biotechnology sector, often occurring as part of pre-planned diversification strategies or to cover tax liabilities associated with the vesting of equity awards.
Comparison to Industry Standards
- The sale of shares by an EVP is consistent with standard executive compensation liquidity events observed across the mid-cap biotechnology industry.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale represents a small portion of the executive's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the reported stock sale transaction. |
| 05/22/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Exelixis, EXEL, Insider Trading, Form 4, Biotech, Equity Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.